Ohguni S, Notsu K, Tanaka J, Sato T, Kato Y
Department of Medicine, Shimane Medical University, Izumo, Japan.
Nihon Naibunpi Gakkai Zasshi. 1993 Aug 20;69(7):650-8. doi: 10.1507/endocrine1927.69.7_650.
Glucose-induced insulin secretion, 24-h urinary C-peptide (CPR) and euglycemic clamp were examined in five patients with hyperthyroid Graves' disease before and 2 weeks after treatment with arotinolol (20 mg/day, p.o.). Plasma glucose and insulin responses to oral administration of 75 g glucose were not changed by arotinolol treatment. 24-h urinary CPR and basal posthepatic insulin delivery rate (BPIDR) as an indicator of insulin secretion were significantly suppressed by arotinolol. Glucose infusion rate (GIR) as an indicator of insulin sensitivity and glucose clearance rate (GCR) were not influenced by arotinolol therapy. Insulin clearance rate (ICR) was significantly suppressed by arotinolol. These findings suggest that arotinolol inhibits insulin secretion by decreasing ICR but does not attenuate insulin release induced by glucose in hyperthyroid patients, and that insulin sensitivity and GCR are not affected by arotinolol.
对5例甲状腺功能亢进的格雷夫斯病患者在使用阿罗洛尔（20毫克/天，口服）治疗前及治疗2周后进行了葡萄糖诱导的胰岛素分泌、24小时尿C肽（CPR）和正常血糖钳夹试验。阿罗洛尔治疗后，口服75克葡萄糖时的血浆葡萄糖和胰岛素反应未发生变化。阿罗洛尔显著抑制了作为胰岛素分泌指标的24小时尿CPR和肝后基础胰岛素释放率（BPIDR）。作为胰岛素敏感性指标的葡萄糖输注率（GIR）和葡萄糖清除率（GCR）不受阿罗洛尔治疗的影响。阿罗洛尔显著抑制了胰岛素清除率（ICR）。这些发现表明，阿罗洛尔通过降低ICR抑制胰岛素分泌，但不会减弱甲状腺功能亢进患者中葡萄糖诱导的胰岛素释放，并且胰岛素敏感性和GCR不受阿罗洛尔影响。
